CD19 as a Predictive Biomarker in Aggressive B-Cell Lymphoma: A Guide for the CAR-T and Bispecific Era

Introduction

The advent of CD19-directed cellular and antibody therapies has transformed the management landscape for relapsed or refractory aggressive B-cell lymphomas. With this transformation comes a new diagnostic responsibility: documenting whether the therapeutic target—CD19—is actually present on a patient's tumor. This article reviews CD19 as a predictive biomarker, explaining what its assessment measures, how it is tested, and how the results inform eligibility for a class of targeted therapies. Throughout, the goal is educational clarity for a mixed audience of pathologists, oncologists, trainees, and informed patients.

What the Test Measures: A Brief Biology

CD19 is a transmembrane glycoprotein expressed across nearly the entire lifespan of the B-cell lineage, from early pre-B stages through mature B cells, and it is retained on the majority of B-cell neoplasms. This broad, lineage-restricted expression is precisely what makes CD19 an attractive therapeutic target: it is present on tumor cells but largely absent from non-B-lineage tissues, and the B-cell aplasia that results from targeting it is a manageable consequence.

The B-cell lymphomas in which CD19 assessment is most clinically relevant—diffuse large B-cell lymphoma and related aggressive entities—are defined within the current framework of the 5th edition of the World Health Organization classification of lymphoid neoplasms [1]. Within that framework, CD19 functions not as a diagnostic discriminator between entities but as a therapeutic target whose presence or absence carries predictive weight.

How It Is Tested: Assay, Specimen, and Scoring

CD19 expression can be evaluated by two principal methods, each with distinct strengths.

Flow cytometry is performed on fresh specimens—peripheral blood, bone marrow aspirate, or disaggregated tissue. It offers quantitative, single-cell resolution, allowing the pathologist to gate on the neoplastic population and assess antigen intensity directly. Because flow requires viable cells in suspension, specimen freshness and prompt processing are essential; delays degrade cell viability and can compromise interpretation.

Immunohistochemistry (IHC) is performed on formalin-fixed, paraffin-embedded (FFPE) tissue. IHC preserves tissue architecture, permitting correlation of antigen expression with morphology, and is applicable to archived material. Preanalytic factors—fixation time, antibody clone, and staining protocol—influence sensitivity and must be controlled.

For this predictive application, scoring is fundamentally binary: expression is either present (CD19+) or lost (CD19−). This contrasts with graded or percentage-based scoring systems used for some other biomarkers. The clinically actionable question is whether the tumor retains the target the therapy is designed to engage.

What Each Result State Means

CD19+ (expression present): The neoplastic B cells retain the target antigen. The therapeutic construct—whether an engineered T cell or a bispecific antibody—has a molecular docking site on the tumor.

CD19− (antigen escape): The neoplastic cells lack detectable CD19. This state is of particular importance because antigen loss is a recognized mechanism of resistance to CD19-directed therapy [2]. Antigen escape may be present at baseline or may emerge after therapy, as tumor subclones lacking the target are selected under treatment pressure. The literature examining why CD19 CAR-T therapy fails in diffuse large B-cell lymphoma identifies loss of the target antigen as one contributor among several to treatment failure [2].

It is worth emphasizing for trainees that a "CD19−" result by one modality warrants thoughtful interpretation. Apparent antigen loss can reflect true biological escape, but it can also arise from technical factors—epitope masking, suboptimal fixation, or antibody clones that recognize different portions of the molecule. Correlation between IHC and flow findings, and awareness of preanalytic history, strengthens confidence in the result.

What It Determines for Treatment Eligibility

The central predictive role of CD19 assessment is to inform eligibility for CD19-directed therapy classes. Specifically, CD19 is the target of:

• CD19 CAR-T cell therapy, in which a patient's T cells are engineered to recognize CD19; and
• CD19/CD3 bispecific antibodies, which physically bridge CD19 on tumor cells to CD3 on T cells to redirect cytotoxicity.

Both are used in the relapsed or refractory aggressive B-cell lymphoma setting [2]. Documented CD19 expression supports eligibility for these therapy classes, whereas confirmed antigen loss identifies a resistance mechanism that may render them ineffective.

This is an educational framing of eligibility, not a treatment recommendation. The presence of CD19 does not by itself dictate that any specific therapy should be administered; treatment decisions integrate disease biology, prior therapy, patient fitness, and clinical judgment. The pathologist's contribution is to determine, as accurately as the assays allow, whether the target is present.

Caveats and What Is Evolving

Several points remain unsettled or are actively evolving, and the evidence suggests caution rather than certainty.

First, the binary "present versus lost" framework is a simplification. In practice, CD19 expression exists on a continuum of intensity, and the threshold at which reduced-but-detectable antigen still permits effective therapeutic engagement is not firmly defined. This mirrors debates in other domains—such as contested "low-expression" cutoffs for targets like HER2 in solid tumors—where the boundary between "positive" and "negative" carries real therapeutic consequences yet lacks universal consensus.

Second, antigen escape is dynamic. A CD19+ result at one timepoint does not guarantee persistence; resistance can develop through antigen downregulation or loss during the course of therapy [2]. Serial or post-progression biopsy may therefore be informative when disease recurs after CD19-directed treatment.

Third, antigen loss is only one of several resistance mechanisms. The literature makes clear that CAR-T failure in diffuse large B-cell lymphoma is multifactorial, and a CD19+ tumor may still fail to respond for reasons unrelated to the target [2]. CD19 status is thus necessary but not sufficient to predict outcome.

Finally, assay standardization across laboratories—optimal antibody clones, flow gating strategies, and reporting conventions—continues to mature. As CD19-directed therapies proliferate, harmonized approaches to documenting the target will grow in importance.

Conclusion

CD19 testing by IHC or flow cytometry answers a focused, predictive question: is the therapeutic target present or lost? A CD19+ result informs eligibility for CD19 CAR-T and CD19/CD3 bispecific therapy classes, while CD19− (antigen escape) flags a recognized resistance mechanism. Understanding the assay's constraints and the evolving nature of antigen escape allows the pathologist to deliver a result that is both accurate and clinically meaningful.

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2.

2. CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail? PMC / peer-reviewed journal. 2024. PMCID: PMC10964476.